Adipose Redistribution in Human Immunodeficiency Virus–Seropositive Patients: Association with CD4 Response
Open Access
- 1 December 2000
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (6) , 1497-1498
- https://doi.org/10.1086/317483
Abstract
We have noted that human immunodeficiency virus (HIV)-seropositive patients who develop adipose redistribution (AR) while receiving combination antiretroviral therapy (ART) also tend to have a better response to ART, as indicated by the relative change in CD4 percent compared to those who don't develop AR on therapy. Whether the possible benefits of the improved CD4 response outweigh the metabolic and cosmetic problems associated with lipodystrophy is not known.Keywords
This publication has 6 references indexed in Scilit:
- A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapyAIDS, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998